The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists
| Autor: | A. Marfat, J. W. Watson, Kelvin Cooper, David B. Damon, James F. Eggler, Lawrence S. Melvin, Hiroko Masamune, John B. Cheng, J. Delehunt, R. J. Chambers |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Leukotriene D4
Platelet-activating factor medicine.drug_class Organic Chemistry Clinical Biochemistry Pharmaceutical Science respiratory system Pharmacology Receptor antagonist Biochemistry chemistry.chemical_compound Orally active chemistry Drug Discovery medicine Molecular Medicine lipids (amino acids peptides and proteins) Pharmacophore Receptor Molecular Biology |
| Zdroj: | Bioorganic & Medicinal Chemistry Letters. 5:1377-1382 |
| ISSN: | 0960-894X |
| Popis: | The combination of key structural pharmacophores found in known leukotriene D4 (LTD4) receptor antagonists with those of potent platelet activating factor (PAF) receptor antagonist UK-74,505 has led to the synthesis of hybrid compounds CP-96,021 and CP-96,486. These compounds represent the first known balanced, combined and orally active LTD4/PAF receptor antagonists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect